Colorectal cancer (CRC) is the third most common type of cancer worldwide, with an estimated 1 million new cases and a half million deaths each year. 1 Early diagnosis is fundamental in reducing morbidity and mortality, with patients diagnosed at early stages demonstrating increased long-term survival. Lack of specificity and sensitivity preclude the use of all existing serum markers for the early detection of CRC. 2, 3 Although 90% of CRCs produce carcinoembryonic antigen (CEA), elevated serum levels are often not found at the time of diagnosis because CEA enters the portal circulation and is metabolized on first pass through the liver. In a screened population, only about 13% of people with positive CEA values were given a diagnosis of CRC. Thus, although screening may occasionally detect patients with resectable disease, the unacceptable false-positive rate and prohibitive costs coupled with the lack of specificity have led to recommendations against CEA testing for CRC screening (reviewed by Goldstein and Mitchell 4 ).
Elevated circulating cell-free DNA (CFD) levels were found in patients with cancer. The standard CFD assays are work-intensive and expensive. The aim was to evaluate in patients with cancer a new simple CFD assay. In mice inoculated with cancer cells, CFD levels correlated with tumor size. Compared with healthy subjects, 38 patients with colorectal cancer (CRC) had higher preoperative CFD levels (798 ± 409 vs 308 ± 256 ng/mL; P < .0001). Compared with patients free of disease at 1 year, CFD levels were elevated in patients who remained with disease or died (DD). CFD correlated with DD (P = .033), and a combined index of carcinoembryonic antigen × CFD exhibited a better correlation to DD than did pathologic staging (P = .0027 vs P = .0065). For patients with CRC, CFD levels were prognostic of death and disease. A large prospective study will need to be performed to truly evaluate the efficacy of this method for early detection, follow-up, and evaluation of patient response to treatment.
Colorectal cancer (CRC) is the third most common type of cancer worldwide, with an estimated 1 million new cases and a half million deaths each year. 1 Early diagnosis is fundamental in reducing morbidity and mortality, with patients diagnosed at early stages demonstrating increased long-term survival. Lack of specificity and sensitivity preclude the use of all existing serum markers for the early detection of CRC. 2, 3 Although 90% of CRCs produce carcinoembryonic antigen (CEA), elevated serum levels are often not found at the time of diagnosis because CEA enters the portal circulation and is metabolized on first pass through the liver. In a screened population, only about 13% of people with positive CEA values were given a diagnosis of CRC. Thus, although screening may occasionally detect patients with resectable disease, the unacceptable false-positive rate and prohibitive costs coupled with the lack of specificity have led to recommendations against CEA testing for CRC screening (reviewed by Goldstein and Mitchell 4 ).
The American Society of Clinical Oncology and the European Group on Tumour Markers recommend testing CEA preoperatively for baseline as an independent prognostic factor and postoperatively for surveillance of patients with stage II or III disease and for monitoring therapy in advanced CRC. 2, 3 According to a recent quantitative meta-analysis of 20 studies, CEA had a high specificity (0.904) for excluding CRC recurrence and a rather modest sensitivity (0.639) for the diagnosis of disease recurrence. 5 Thus, the existing tests have limited power for early detection and follow-up of patients with CRC, and additional serologic markers are needed.
The presence of elevated levels of cell-free circulating DNA (CFD) in the blood of patients with cancer was initially demonstrated by Leon et al 6 in 1977 . This study was a milestone in diagnostic medicine because it was the first time the clinical potential of circulating nucleic acids as a molecular marker in cancer had been explored. The easy accessibility of plasma and serum DNA has made these noninvasive approaches to identify and follow up patients with cancer an appealing method. Many studies have confirmed the initial observation of Leon et al 6 and found elevated CFD levels in patients with malignancy (reviewed by Gormally et al 7 ) , including patients with CRC. [8] [9] [10] [11] The elevation in circulating CFD levels originates through the release of DNA from cellular necrosis and apoptosis of tumor cells 12, 13 and probably from dying cells in the surrounding tissue affected by the tumor.
Although there is general agreement on the value of CFD measurement for patients with cancer, to date there is no standard applicable method for routine clinical use. The currently available research methods for CFD measurement are work-intensive and expensive, requiring DNA extraction and real-time polymerase chain reaction amplification with specific primers. Consequently, CFD measurements are not used during routine management of patients.
We recently developed a convenient DNA assay applied directly to biologic samples. 14 This assay uses the fluorochrome SYBR Gold (Invitrogen, Paisley, Scotland), 15 which does not require prior processing of samples, ie, DNA extraction and amplification. The assay is simply performed by adding diluted fluorochrome to the samples and measurement of fluorescence. The assay is accurate, sensitive, and reproducible.
The aim of the present study was to evaluate this new method for the identification and follow-up of cancer progression in an animal model and in patients with CRC.
Materials and Methods

Mouse Tumor Model
CD1 mice (Harlan, Jerusalem, Israel) were maintained in the animal laboratory of the Soroka Medical Center, Be'er Sheva, Israel. The MCA-2 cell line was generated in our laboratory from a 3-methylcholanthrene-induced solid tumor (fibrosarcoma) in CD1 mice according to Reddy and Fialkow. 16 When injected into CD1 mice, these cells grow to a solid tumor that is rejected 2 weeks from inoculation (unpublished data, H.E. et al, 2008). MCA-2 cells were maintained in Dulbecco modified eagle medium containing 10% heat-inactivated fetal calf serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (Biological Industries, Beth Haemek, Israel). Suspension of MCA-2 cells in phosphate-buffered saline (PBS) was injected into the rear left footpad of CD1 mice (n = 10, 10 6 cells per mouse). Local tumor growth was determined by measurement of the footpad diameters 2 to 3 times a week using a caliper. The tumor volume was calculated by using the formula: V = 0.4 × ab 2 , where a and b are the maximum and the minimum tumor diameters, respectively. 17 Following tumor measurement, mice were bled from the tail artery (50 μL), and serum samples were kept at -20°C until assayed for CFD levels. Experiments were conducted with the approval of the Israel Committee for Animal Experiments.
Human Subjects
For the study, 38 unselected patients with confirmed primary CRC were recruited; 21 (55%) were women and 17 (45%) were men. The age range was 43 to 86 years, and the mean age was 68 years. The primary colon carcinoma sites were as follows: right colon, 17 (47%); sigmoid colon, 9 (25%); left colon, 5 (14%); rectum, 4 (11%); and simultaneous carcinoma in the right and left colon, 1 (3%). Blood samples were obtained a week before surgery. The concentration of CEA was determined by using the ARCHITECT CEA assay (Abbott Laboratories, Abbott Park, IL). For CFD level determination, serum was separated from the cellular fraction and frozen at -20°C until assayed. Preoperative CEA levels were tested in 35 (92%) of 38 patients. One patient died of surgery-induced complications and was excluded from the follow-up study.
CFD reference values were established by analysis of serum samples from 34 healthy volunteers from the small community village "Kibbutz Mashabei Sade." These volunteers joined the study following local advertisement. Their health conditions were certified by their family physicians, who relied on interrogations and their medical records. Volunteers with acute or chronic disease were excluded. The normal cohort was composed of 19 women and 15 men with a mean age of 48 years (range, 30-84 years). Blood samples (3 mL) were collected from patients and volunteers using BD Vacutainer gel tubes (Becton Dickinson, Plymouth, England). Serum was separated by centrifugation and stored at -20°C until assayed for CFD levels.
The research protocol was approved by the local ethics committee of the Soroka Medical Center. Written informed consent was obtained from all patients and volunteers who participated in the study.
CFD Assay
CFD was detected directly in serum samples according to a method published recently. 14 Briefly, SYBR Gold Nucleic Acid Gel Stain (Invitrogen) was diluted first at 1:1,000 in dimethyl sulfoxide (Sigma-Aldrich, Rehovot, Israel) and then at 1:8 in PBS. Eight DNA standards (0 ng/mL and 7 serial dilutions from 78 to 5,000 ng/mL) were prepared with commercial salmon sperm DNA (Sigma-Aldrich) in PBS containing 10% bovine serum albumin (Sigma-Aldrich). Ten microliters of serum samples or DNA standard solutions were applied in duplicate to black 96-well plates (Greiner Bio-One, Frickenhausen, Germany); 40 μL of diluted SYBR Gold was added to each well (final dilution, 1:10,000), and fluorescence was measured with a 96-well fluorometer (Spectrafluor Plus, Tecan, Durham, NC) at an emission wavelength of 535 nm and an excitation wavelength of 485 nm. Concentrations of unknown samples were calculated from a standards curve by extrapolation in a linear regression model. Usually, the goodness of fit of the standards curve (r 2 ) was higher than 0.97. To confirm the specificity of the assay, 10 randomly selected samples from the CRC group were incubated at 37°C for 5 hours with DNase (500 U/mL, 5 PRIME, Gaithersburg, MD).
Statistics
Statistical analysis was performed with GraphPad Prism software (version 5.01; San Diego, CA). Statistically significant differences between 2 groups were tested by using the t test or the nonparametric Mann-Whitney test. For comparison of more than 2 groups, we used analysis of variance followed by the Tukey multiple comparison test or nonparametric Kruskal-Wallis test followed by the Dunn multiple comparison test. Correlation was analyzed by using the Spearman test. Results are given as mean or median ± SD.
Results
To establish a correlation between CFD levels and tumor development, mice were injected intrafootpad with MCA-2 cancer cells, and CFD levels were measured according to our new method. MCA-2 cells are highly immunogenic and were found to be rejected by the host 2 weeks after injection (nonpublished observation). As shown in ❚Figure 1❚, during the 2 weeks of tumor expansion, as well as in the rejection phase, CFD levels in mice followed tumor development and correlated with tumor size (P = .015). Starting at day 6 from inoculation, CFD levels were significantly elevated before the appearance of the tumor (day 8). The tumor size and CFD levels concomitantly peaked at day 14 and declined at day 18.
In accordance with our findings in mice, elevated median CFD levels with a value of 798 ± 409 ng/mL (range, 165-2,590 ng/mL) were found in a cohort of 38 patients with CRC compared with a value of 308 ± 256 ng/mL (range, 0-968 ng/mL) in 34 healthy subjects ❚Figure 2A❚ (P < .0001). CFD levels did not correlate with age (P = .40 for control and P = .95 for CRC group) or sex (P = .21 for control and P = .50 for CRC group) in either group. The specificity of the assay to DNA was confirmed by treatment with DNase of 10 randomly selected serum samples from the CRC group. The mean value of these samples was reduced from 720 ± 305 ng/mL (not shown) to 94 ± 67 (Figure 2A) . To determine the upper CFD cutoff levels, we performed a receiver operating characteristic curve analysis and found an area under the curve of 0.84 ❚Figure 2B❚. The maximal likelihood ratio (7.16) for specificities of 90% to 95% was 841 ng/mL, and this value was chosen as the upper CFD cutoff. The calculated sensitivity for detection of CRC in our cohort was 42%, and the specificity was 94%. To evaluate our biomarker, we compared it with CEA, which is the "gold standard" for the follow-up of recurrence of CRC. As shown in ❚Figure 3❚, the sensitivity of preoperation CFD to detect the primary tumor was higher compared with CEA (40% vs 28%, respectively). No correlation was found between CEA and CFD in our cohort (Spearman correlation, P = .29; Figure 3B ) ❚Table 1❚. The overlap between positive samples was partial, and only 17% (6/35) of the patients were double-positive for CEA and CFD. Together, 51% (18/35) of the patients were positive for 1 or 2 markers. At the indicated time points, tumor size was measured using a caliper and mice were bled (50 μL) from the tail artery. Mice serum samples were analyzed for CFD levels using the SYBR Gold method. Relative CFD levels are indicated in arbitrary fluorescence units at 535 nm (F 535 ). The tumor volume of each mouse at each time point was correlated with matched CFD levels (Spearman correlation, P = .0153; ρ = 0.29). Significant differences from time 0 with * P < .05; † P < .01; and ‡ P < .001. CEA correlated with pathologic stage (P = .007; ρ = 0.45, Table 1 ). The percentage of CEA+ cases increased gradually according to grade: 0% (0/5) for I, 6% (1/16) for II, 63% (5/8) for III, and 80% (4/5) for IV ❚Figure 4B❚. In contrast with CEA, CFD did not correlate with pathologic stage. The CFD threshold was more sensitive than CEA for detecting patients with stage I (50% [3/6] At 1 year from surgery, 4 patients had died of disease, 2 patients were diagnosed with stage IV tumors and 1 with stage III, and 1 was diagnosed as having a stage II tumor and died of a recurrent disease. One additional patient died of surgery-induced complications and was excluded from the follow-up study. Preoperative levels of CFD and CEA were significantly elevated in the dead or with disease (DD) group compared with the disease-free group ❚Figure 5❚. Of 16 CFD+ patients, 7 were in the DD group (true positive, 44%). Of 8 patients in the DD group, 7 were CFD+ (88% specificity), and CFD levels correlated with DD (P = .033; Table 1 ). From 10 CEA+ cases, 5 were in the DD group (50%). Of 8 patients in the DD group, 5 had elevated preoperative CEA levels (63% specificity), and CEA levels correlated with DD (P = .01). The combined index of CEA × CFD exhibited a better correlation and correlation coefficient (P = .0027) with DD than each marker alone (P = .01 for CEA and P = .03 for CFD). Moreover, this combined index had a favorable correlation and correlation efficiency to DD than pathologic staging (P = .0027 vs P = .0065; ρ = 0.49 vs 0.44). 
Discussion
This is the first study on cancer in which our innovative and simple technique to measure CFD levels was applied. Various complex techniques have been used in previous evaluations of CFD levels in patients with cancer, including studies on CRC. For these evaluations, DNA was extracted from blood, and its concentration in the extract was measured by quantitative polymerase chain reaction or other techniques. [8] [9] [10] [11] In contrast, our assay eliminates the complex extraction phase, and DNA is measured directly in the diluted samples using a fluorescent dye. 14 We first validated that CFD levels measured by our assay reflect tumor progression in an animal model. In mice inoculated with cancer cells, tumor growth and CFD levels correlated and concurrently peaked at day 14 and declined with tumor rejection at day 18. Notable is the elevation of CFD levels at day 6, which preceded the appearance of the tumor at day 8. Also important to note is the associated decline of CFD levels with tumor rejection, which suggests the possible use of this marker not only for detection and follow-up but also for following up the response to treatment. These encouraging findings in animals initiated the prospective study in 38 human subjects with CRC. The CFD levels in our cohort of patients with CRC were significantly higher than in the control group with a median CFD value of more than double that of the control group (798 vs 317 ng/mL). Elevated CFD levels have been previously described in several studies. For example, Schwarzenbach et al 11 measured CFD levels in serum samples of 55 patients with CRC by a different method and also detected increased CFD levels in the CRC group compared with the control group. Since previous studies used various extraction and DNA-quantitation techniques, it is not possible to compare the absolute concentration we found with those found in the aforementioned studies.
We compared the CFD levels in our patients with CRC with CEA levels, the best available serologic marker for recurrence of CRC. 2, 3 With the high specificity of 94%, our CFD assay had a sensitivity of 40%, higher than the sensitivity of CEA (28%). In our cohort of patients, CFD and CEA did not correlate. This lack of correlation between these markers could be explained by their different biology: CEA is exclusively released from some of the tumors, while CFD is released from dead cells of the tumor and the affected surrounding tissue. In 17% of the CRC serum samples, mainly from patients with stage IV tumors, there was double positivity for CFD and CEA. CFD was advantageous in detecting almost 50% of the samples from patients with low-stage tumor. In contrast, CFD had low sensitivity for samples from patients with stage III tumors, while more than 50% of these samples were CEA+. Similar to our findings, Flamini et al 8 found lower CFD levels in patients with Duke stage C disease. One can speculate that the invasive nature of tumors in stage III allows them to grow with less destruction or with less involvement of antitumor immune activity. It may also be supported by the clinical observation of the lack of a survival benefit of adjuvant chemotherapy in patients with stage II colon cancer compared with patients with stage III disease. 18 In their study, Flamini et al 8 compared CEA and CFD and concluded that both markers provided independent diagnostic information and that in combination they had higher diagnostic capacity than each marker singly. 8 Similarly, our data indicate that combining the 2 markers might be beneficial for the detection of primary tumors. When both markers were combined, 50% of patients were positive for 1 or 2 markers. Furthermore, reduction of the CFD cutoff to a specificity of 82% increased the combined detection sensitivity to 80%.
Elevated presurgery CEA and CFD levels were associated with death or disease at 1 year from resection. It is important to note that we found that the combined index (CEA × CFD) was more prognostic than either marker alone and showed even better association with DD than the pathologic stage, the prognostic gold standard (P = .0027 vs P = .0065).
By using a simple fluorometric assay, we were able to measure CFD levels and follow tumor growth and rejection in mice. In humans, we confirmed the findings of previous studies that were performed with a complex and time-consuming method and found elevated CFD levels in patients with CRC. Elevated CFD levels were prognostic of death and disease, and a combined index with CEA was more associated with DD than pathologic stage. A large prospective study will need to be performed to truly evaluate the efficacy of this method for early detection, follow-up, and evaluation of patient response to treatment.
